Karma Biotechnologies is solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform.
Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic immunotherapies that elicit antigen-specific immune tolerance in vivo.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 1, 2021 | Seed | $2.78M | 1 | — | — | Detail |